NKTR Reports $21.8M Q4 Rev, $55.2M FY Rev, $164.1M Net Loss, $8.66 Non-GAAP EPS, $245.8M Cash, $432M Offering Proceeds, Phase 3 June Start
Nektar Therapeutics · PHARMACEUTICAL PREPARATIONS · Now $63.86
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS